DNA Sequencing Biotechnology | Retrogen, Inc.

Posted by Retrogen, Inc. on February 12th, 2021

Retrogen’s Clinical Laboratory Services are run under guidelines regulated by the Clinical Laboratories Improvement Amendments (CLIA) and under accreditation by the College of American Pathologist. Next-Gen and Sanger based genomics workflows have been optimized to provide industry leading quality and reliability.

Along with you, we are closely watching the impact COVID-19 is having within our communities, and as the outbreak continues, we want to ensure you Retrogen is taking measures to decrease the transmission. We have instructed all staff to follow the CDC Prevention Guidelines to keep our employees and communities safe.

Next-generation sequencing (NGS) offers the NIPT scalability, speed, and resolution to evaluate targeted genes of interest. Multiple genes can be assessed across many samples in parallel, saving time and reducing costs associated with running multiple separate assays. Targeted gene sequencing also produces a smaller, more manageable data set compared to broader approaches such as whole-genome sequencing, making analysis easier.

All clinical applications will be performed under CLIA/CAP guidelines by trained personnel. Research projects have the option of performing work under clinical conditions, but without QA and medical director release. Applications not requiring clinical operations may be run in research use only (RUO) laboratory, always by Retrogen’s skilled personnel.